


**Bereskin & Parr**


Barristers and Solicitors/Patent and Trade Mark Agents  
Practice Restricted to Intellectual Property Law

Micheline Gravelle B.Sc., M.Sc. (Immunol.)  
416 957 1682 mgravelle@bereskinparr.com

Your Reference: 10/046,542  
Our Reference: 7685-41

May 14, 2002

The Commissioner of Patents  
& Trademarks  
Washington, D.C. 20231  
U.S.A.

**Attention: Box Missing Parts**

Dear Sir:

**Re: NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL  
APPLICATION  
United States Patent Application No. 10/046,542  
Entitled: Method of Enhancing an Immune Response  
Inventors: Wilfred A. Jefferies et al.  
Filing Date: January 16, 2002  
Art Unit: 1632**

---

This is in response to the Notice to File Missing Parts of Nonprovisional Application - Filing Date Granted mailed February 15, 2002, a copy of which we attach. Applicants are simultaneously filing a Petition for Extension of Time (one month) rendering the due date for response **May 15, 2002**.

Please amend the application as follows:

**In the Specification**

Please replace the paragraph beginning at page 58, line 1, with the following rewritten paragraph:

--removed and cultured in RPMI-1640 complete medium containing 10% heat-inactivated HyClone FBS (GIBCO BRL), L-glutamine, 100IU/ml penicillin, 100mg/ml streptomycin, Hepes, 0.1 mM non-essential amino acids, 1 mM Na-pyruvate, and 50 mM 2-ME. The splenocyte cultures were incubated at  $3 \times 10^6$  cells/ml at 37°C for 3 days with the peptide (1  $\mu$ M Sendai-Np 324-332 peptide, FAPGNYPAL (SEQ ID NO:6)) for Sendai-specific effectors or without a peptide for

VSV-specific effectors. The erythrocytes were removed from the splenocytes before 3 days culture (for VSV-specific effectors) or after (for Sendai-specific effectors).--

Please replace the paragraph beginning at page 63, line 1, with the following rewritten paragraph:

--using the following primer sets: GACCGGACTCTGGACAGC (SEQ ID NO:4) and GTAAATTCCGGGGCATCTCCT (SEQ ID NO:7) corresponding to rat TAP1: AGGAAGCAGATTTTCAGAACTC (SEQ ID NO:8) and AGTCCTGAGAGGGCTCAG TGT (SEQ ID NO:9) corresponding to rat TAP2 respectively. The  $\beta$ -actin subunit primer set was obtained from Ambion. For all targets, the PCR reaction consisted of 30 cycles of amplification at an annealing temperature of 56°C using Platinum Taq polymerase (Invitrogen), according to manufacturer's instructions. One tenth of the product of each PCR reaction was examined by agarose gel electrophoresis. The inventors measured the intensity of  $\beta$ -actin product in order to ensure that the reaction kinetics and starting material of cDNA in each reaction was equivalent.--

Please replace the paragraph beginning at page 63, line 22, with the following rewritten paragraph:

--For tyrosinase-related protein 2 (TRP-2) specific CTL generation, the specificity of splenocytes was generated by injecting mice intraperitoneal with  $3 \times 10^6$   $\gamma$ -irradiated RMA-S cells pulsed with 5  $\mu$ M, K<sup>b</sup>-restricted TRP-2 peptides (SVYDFFVWL (SEQ ID NO:10)) for 5 days. Upon removal the splenocytes were cultured with 1  $\mu$ M TRP-2 for 6 days and used for bulk-culture CTLs in a standard 4 h <sup>51</sup>Cr release assay.--

Please insert Sequence Listing pages 89-91 into the specification.